Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Allergen or component thereof
Reexamination Certificate
2007-05-08
2007-05-08
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Allergen or component thereof
C424S184100, C424S234100
Reexamination Certificate
active
09561089
ABSTRACT:
Methods are provided for the treatment of allergic and other immune disorders associated with overproduction of Th2 type cytokines by antigen specific T cells. Immunotherapy with adjuvants, as provided in the present invention, greatly inhibits the development of airway hyperreactivity and airway inflammation. Such immunotherapy is shown to reverse ongoing airway disease, and convert allergic inflammatory responses into protective immune responses. Conditions of particular interest include allergic conditions associated with production of Th2 cytokines and/or IgE antibodies, asthma, allergic rhinitis, and anaphylactic reactions. The addition of adjuvant induces a Th1-type immune response and can redirect an established Th2-type response to a Th1-type response for the selected antigen. Preferably, antigen-specific IgE production is reduced without altering the intensity of the antigen-specific proliferative response. One particularly preferred adjuvant for use in accordance with the present invention is aListeriaadjuvant.
REFERENCES:
patent: 4180563 (1979-12-01), Fauve
patent: 5679349 (1997-10-01), Scheifinger et al.
patent: 5698679 (1997-12-01), Nemazee
patent: 5935568 (1999-08-01), Dow et al.
patent: WO 98/16247 (1998-04-01), None
patent: WO 00/06588 (2000-02-01), None
US 6,008,200, 12/1999, Krieg (withdrawn)
Baldridge et al. Vaccine 15(4):395-401, 1997.
Schwartz et al. Am J Physiol Lung Cell Mol Phys. 280:L771-L778, 2001.
Bosquet, et al. (1991) “Differences in Clinical and Immunologic Reactivity of Patients Allergic to Grass Pollens and to Multiple-Pollen Species,”J. Aller. Clin. Immunol.vol. 88(1):43-53.
Creticos, et al. (1992) “Immunotherapy With Allergens,”J.A.M.A.vol. 268(20):2834-2839.
Creticos, et al. (1996) “Ragweed Immunotherapy in Adult Asthma,”N. Eng. J. Med.vol. 334:501-506.
DeKruyff, et al. (1997) “Antigen-Driven but Not Lipopolysaccharide-Driven IL-12 Production in Macrophages Requires Triggering of CD40,”J. of Immunologyvol. 158:359-366.
Gavett, et al. (1995) “Interleukin12 Inhibitors Antigen-induced Airway Hyperresponsiveness, Inflammation, and Th2 Cytokine Expression in Mice,”J. Exp. Med.vol. 182:1527-1536.
Hsieh, et al. (1993) “Devleopment of TH1 CD4+T Cells through IL-12 Produced byListeria- Induced Macrophages,”Sciencevol. 260:547-549.
Hsu, et al. (1996) “Immunoprophylaxis of Allergen-Induced Immunoglobulin E Synthesis and Airway Hyperresponsivenessin viviby Genetic Immunization,”Nature Medicinevol. 2(5):540-544.
Kim, et al. (1997) “An Ovalbumin-IL-12 Fusion Protien is More Effective than Ovalbumin Plus Free Recombinant IL-12 in Inducing a T helper Cell Type 1-Dominated Immune Response and Inhibiting Antigen-Specific IgE Production,”J. of Immunologyvol. 158:4137-4144.
Kiniwa, et al. (1992) “Recombinant Interleukin-12 Suppresses the Synthesis of Immunoglobulin E by Interleukin-4 Stimulated Human Lymphocytes,”J. Clin. Invest.vol. 90:262-266.
Marshall, et al. (1995) “IL-12 Inhibits the Production of IL-4 and IL-10 in Allergen-Specific Human CD4+T Lymphocytes,”J. of Immunologyvol. 155:111-117.
Miller, et al. (1996) “Protective Immunity toListeria MonocytogenesElicited by Immunization with Heat-KilledListeriaand IL-12,”Annals of the New York Acad. of Sci.vol. 797:207-227.
Nelson, (1997) “Does Allergen Immunotherapy Have a Role in the Treatment of Bronchial Asthma?”Allergy and Asthma Proc.vol. 18:157-162.
Okamura, et al. (1995) “Cloning of a New Cytokine that Induces IFN-γ Production by T Cells,”Naturevol. 378-88-91.
Secrist et al. (Dec. 1993), “Allergen Immunotherapy Decreases Interleukin 4 Production in CD4+T Cells from Allergic Individuals.”J. Exp. Med.,vol. 178:2123-2130.
Söderlund, et al. (1997) “Allergen Induced Cytokine Profiles in Type I Allergic Individuals Before and After Immunotherapy,”Immunology Lettersvol. 57:177-181.
Tripp et al. (1994), “Neutralization of IL-12 Decrease Resistance toListeriain SCID and C.B-17 Mice.”Journal of Immunology,vol. 152:1883-1887.
Weber, (1997) “Immunotherapy with Allergens,”J.A.M.A.vol. 278:1881-1887.
Yoshimoto, et al. (1997) “Interleukin 18 Together with Interleukin 12 Inhibits IgE Production by Induction of Interferon-γ Production from Activated B Cells,”Proc. Natl. Acad. Sci. USAvol. 94:3948-3953.
Yeung et al. (1998) “Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses.”Journal of Immunology,vol. 161(8):4146-52.
DeKruyff Rosemarie H.
Umetsu Dale T.
Bozicevic Field & Francis LLP
Ewoldt G. R.
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Adjuvant therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adjuvant therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3780048